Market Newsdesk

SEATTLE, Dec. 10, 2020 (GLOBE NEWSWIRE) — 2nd Watch, a leading provider of cloud migration and managed cloud services, has partnered with Armor, a global cloud security and compliance software provider, to deliver a Managed Security service designed to help cloud-centric enterprises navigate the evolving cybersecurity threat landscape by shifting responsibility for IT infrastructure and application monitoring, threat analysis and issue resolution from an enterprise’s IT team to 2nd Watch’s managed cloud security practice.

A study published in May by IDC found that global spending on digital transformation technologies, such as cloud software, would grow over 10 percent in 2020 to $1.3 trillion. Meanwhile, a report published in 2019 by Deloitte found that the use of cloud software increasingly exposes companies to costly cyber-attacks.

To mitigate their risks, cloud-centric enterprises are outsourcing security management to third parties. 2nd Watch has years of experience securing global brands’ public and private workloads with a proven approach based on cloud best practices.

The new service extension, which leverages the Armor Anywhere platform, includes 24x7x365 vSOC monitoring to protect against the latest vulnerabilities; rapid incident remediation; consumption-based pricing; protection across AWS, Microsoft Azure and Google Cloud; industry-leading malware protection; supported log ingestion from 200+ third-party sources; and a single point of contact for security management via 2nd Watch.

“2nd Watch offers the industry’s most comprehensive suite of security solutions for DevOps teams, CISOs and Security Architects to combat threats from both outside and inside your network,” said Chris Garvey, EVP of Product at 2nd Watch. “Our multi-cloud Managed Security service goes beyond best practice recommendations and guidance to include implementation, deployment and full management of security devices along with remediation of identified security issues.”

“Every enterprise should make it a priority to integrate security and compliance protections into their cloud infrastructure so as to guard against both intentional and accidental risks,” said Josh Bosquez, Armor Chief Technology Officer. “Armor Anywhere’s robust workload protection and compliance capabilities, combined with 2nd Watch’s extensive managed cloud services, helps organizations do just that: detect, respond and resolve accidental and intentional threats.”

About 2nd Watch

2nd Watch is an AWS Partner Network Premier Consulting Partner, Google Cloud Partner, and Microsoft Azure Gold Partner, providing professional and managed cloud services to enterprise clients. The company’s subject matter experts and software-enabled services provide companies with tested, proven, and trusted solutions with a focus on six solution areas – Enterprise Cloud Migration, Security and Compliance, Cloud Native and DevOps, Optimization, Data Engineering and Analytics, and Managed Services – allowing them to fully leverage the power of the cloud. 2nd Watch solutions are high performing, robust, increase operational excellence, decrease time to market, accelerate growth and lower risk. 2nd Watch helps enterprises design, deploy and manage cloud solutions and monitors business critical workloads 24×7. The company is headquartered in Seattle, Washington. To learn more about 2nd Watch, visit www.2ndwatch.com.

About Armor

Armor is a global cybersecurity software company that simplifies protecting data and applications in private, public or hybrid cloud environments. Armor Anywhere provides technology to detect and respond to threats and can be activated in minutes. Armor also helps organizations comply to major regulatory frameworks and controls. Armor combines workload protection, analytics from cloud-native sources, and other security data to provide unparalleled insight into threats facing organizations. Armor’s cybersecurity experts monitor customer environments 24/7/365 and if an attack takes place, helps customers respond quickly and effectively. Armor protects over1,500 customers in 42 countries. To learn more, visit www.armor.com or follow @armor on Twitter.

Media contact:
Kevin Wolf
TGPR
(650) 483-1552
[email protected]

BELLEVUE, Wash., Dec. 10, 2020 (GLOBE NEWSWIRE) — Auth0, the identity platform for application teams, today announced that it is providing BioReference Laboratories, Inc., an OPKO Health company and a leading provider of laboratory testing services in the U.S., with end-to-end authentication for its patient portal, giving patients HIPAA compliant and secure, direct access to their lab results and medical data. This was essential as COVID-19 hit and BioReference faced a rise in new patient portal users—including a 25x increase in volume overnight—who needed a secure and easy way to monitor their test results.

BioReference provides comprehensive diagnostic solutions to healthcare providers, clinics, hospitals, employers, government units, correctional institutions, medical groups, and more. The laboratory’s vast test menu is utilized in the detection, diagnosis, evaluation, monitoring, and treatment of disease, including COVID-19. In recent months, BioReference has made significant investments in its B2B and B2C offerings, including Customer Digital Solutions, Direct-to-Consumer Solutions, Telehealth, and Patient Empowerment.

“COVID-19 has caused a seven to ten year acceleration in consumer and digital trends,” said Richard Schwabacher, SVP for Digital Health and Chief Digital Officer at BioReference Laboratories. “Securing, transmitting, and authorizing patient access to health information digitally is now critical to the practice of medicine and core to what is needed from a modern digital health solution.”

Identity and access management (IAM) was a key component in BioReference’s transition to providing a more patient-centric model. The company leveraged Auth0 as the IAM in its new patient portal so that patients can securely see results and pay bills, giving patients direct access to their healthcare information. Now, patients no longer have to depend upon their healthcare provider to act as an intermediary to access this information.

“Auth0 helps address concerns about security and user access, especially during times like the present when COVID-19 is causing a significant increase in patient demand,” said Vinny Pacione, VP of Consumer Technology and Digital Solutions at BioReference Laboratories. “Enabling delivery of this data to individuals in a self-service way using scalable, automated digital platforms was a key problem to solve. The most fundamental piece of the solution is securing the data and ensuring that only the individuals who have appropriate authorization can access it.”

“Identity management is a critical component of any digital transformation initiative, and COVID-19 has forced many companies into transition,” said Ghazi Masood, SVP of Americas for Auth0. “BioReference aspires to transform telehealth and put patients at the center of the future of medicine. We are proud to aid them in their journey and help them to deliver a secure, seamless experience for their patients.”

More details on BioReference’s implementation of Auth0 can be found here.

About BioReference Laboratories, Inc.

BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions, and medical groups. BioReference developed and offers test services that yield high quality and accurate results, including a molecular test for helping with COVID-19 diagnosis and a serology test to help indicate possible COVID-19 exposure. The company is in network with the five largest health plans in the United States, operates a network of 11 laboratory locations, and is backed by a medical staff of more than 120 M.D., Ph.D. and other professional level clinicians and scientists. With a leading position in the areas of genetics, women’s health, maternal fetal medicine, oncology, and urology, BioReference and its specialty laboratories, GenPath and GeneDx, are advancing the course of modern medicine. For more information, visit www.bioreference.com.

About Auth0

Auth0 provides a platform to authenticate, authorize, and secure access for applications, devices, and users. Security and application teams rely on Auth0’s simplicity, extensibility, and expertise to make identity work for everyone. Safeguarding billions of login transactions each month, Auth0 secures identities so innovators can innovate, and empowers global enterprises to deliver trusted, superior digital experiences to their customers around the world.

For more information, visit https://auth0.com or follow @auth0 on Twitter.

Media Contacts:

Auth0 Global Communications
[email protected]

Matter for Auth0
[email protected]

BioReference Laboratories Communications
[email protected] 

HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) — Onit, Inc., a leading provider of enterprise workflow solutions, including enterprise legal management, contract lifecycle management and business process automation, has been named to the list of the Houston Chronicle’s Top Workplaces for the third year in a row. The awards program recognizes the most sought-out businesses from more than 14,000 employers in the Houston region.

The list is based solely on employee feedback gathered through a third-party survey and measures 15 drivers of engaged cultures critical to any company’s success, including organizational health, engagement and satisfaction.

In addition to ranking number 30 on the list, Onit earned the program’s only Communications Award. The award, also based on employee feedback, is reserved for the organization continually going above and beyond to keep employees informed.

“Employees are our most valuable asset and an integral part of our mission. They are who make us successful as a company,” said Eric M. Elfman, CEO and co-founder of Onit. “In a time when other companies are reducing workforces, Onit committed to not only protect its employee base but also expand it. By the end of 2020, we will have close to 400 employees globally and plan to continue hiring in the new year.”

Onit takes employee satisfaction seriously, with a full-time director of organizational health and regular methods for evaluating employee engagement and gathering feedback. It also recognized the need for increased two-way communications during challenging times. When the pandemic hit in March, Onit expanded its worldwide town hall meetings from quarterly to biweekly to help its employees understand how conditions are affecting business and how the company is addressing those challenges. Each session also includes Q&A time with Onit leadership, supporting the company’s commitment to transparency.

Onit Careers

For Onit, people are the key to continued innovation and success. Visit Onit Careers to view current job openings and apply.

2020 Awards for Onit


This honor joins a growing list of ones Onit has earned this year. The company has more than 10 this year, many of them linked to the company’s cumulative growth and increased revenue over the past three to five years. Inc. included Onit on its Inc. 5000 (#737) and 250 Fastest-Growing Companies in Texas (#70) as well as its Private Titans list, which names the 1,000 largest iconic private companies in the United States. The Financial Times placed Onit as #153 on its 500 Fastest-Growing Companies in the Americas roster, and Growjo’s list of fastest-growing companies ranked Onit at number four for the city of Houston, 52 for the tech services category, 20 for the state of Texas and 648 on the Growjo 10K.

About Onit
 
Onit is a global leader of workflow and artificial intelligence platforms and solutions for legal, compliance, sales, IT, HR and finance departments. With Onit, companies can transform best practices into smarter workflows, better processes and operational efficiencies. With a focus on enterprise legal management, matter management, spend management, contract lifecycle management and legal holds, the company operates globally and helps transform the way Fortune 500 companies and billion-dollar corporate legal departments bridge the gap between systems of record and systems of engagement. Onit helps customers find gains in efficiency, reduce costs and automate transactions faster. For more information, visit www.onit.com or call 1-800-281-1330.

Media inquiries:

Melanie Brenneman
Onit
(713) 294-7857
[email protected]

 

Addison, TX, Dec. 10, 2020 (GLOBE NEWSWIRE) — American International Holdings Corp. (OTCQB: AMIH) (“AMIH” or the “Company”), a diversified holding company dedicated to acquiring, managing and operating, health, wellness, infrastructure and technology companies, today announced that its subsidiary, ZipDoctor, Inc. (“ZipDoctor”) has commenced its marketing initiatives geared towards companies of all sizes to offer its telemedicine services to their employees as an employment benefit.

The ZipDoctor telemedicine platform, though not a replacement to traditional health insurance, is an affordable alternative to health care whereby employers can provide their employees with unlimited 24/7 access to medical doctors for routine, non-emergency conditions and with additional fees or copays. For a complete list of the medical conditions that can be treated by ZipDoctor, please visit the website at www.zipdoctor.co/what-we-treat/

“There are millions of small businesses across our nation that cannot afford to provide healthcare benefits to their employees. For many of these workers and their families, having access to a doctor through our platform would be a significant quality of life improvement,” commented Jacob Cohen, CEO of American International Holdings Corp.

According to a recent study by the Kaiser Family Foundation (KFF), “In 2019, 73.7% of uninsured adults said that they were uninsured because the cost of coverage was too high.” The Company’s research has discovered that this is a problem affecting the working-class, middle-class and even the upper middle-class alike. Platforms like the ZipDoctor service can help to alleviate the problems associated with lack of insurance. Moreover, the Company believes that it is in the best interest of all business owners to provide some level of support for their respective employee’s well-being – these benefits could improve productivity, decrease absenteeism and even boost employee morale.

Business owners and Human Resource Managers can enroll for a free no-obligation consultation with ZipDoctor, by visiting the Company’s website at, under the “Employers” section or by going to www.zipdoctor.co/employers/.

About ZipDoctor, Inc.

ZipDoctor, Inc. is a monthly subscription based online telemedicine platform providing customers with unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and therapists. ZipDoctor’s online telemedicine platform is available to customers across the United States and offers bilingual coverage (both English and Spanish), with virtual visits taking place either via the phone or through a secured video chat platform. ZipDoctor’s telemedicine platform does not require the customer to have an existing insurance plan and does not demand or require any additional copays. ZipDoctor customers subscribe through the website and are only required to pay a low monthly fee, which is determined based on if they are an individual, a couple, or a family. To learn more about ZipDoctor, visit us online at www.ZipDoctor.co.

About American International Holdings Corp.

American International Holdings Corp. is a diversified holding company dedicated to (a) acquiring, managing and operating health, wellness, infrastructure and technology companies, businesses and/or brands located both in the United States and abroad; (b) operating and managing an online platform providing customers with access to life and career coaches through LifeGuru, Inc. (www.LifeGuru.me, which is currently in development); and (c) operating and managing an online telemedicine platform connecting customers to board certified physicians and licensed mental and behavioral health counselors through ZipDoctor, Inc. (www.ZipDoctor.co). The Company seeks opportunities to acquire and grow businesses that possess strong brand values and that can generate long-term sustainable free cash flow and attractive returns in order to maximize value for the Company and its stakeholders.

FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements, including information about management’s view of the Company’s future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the “Act”). Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management’s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “would,” “could,” “will” and other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company’s actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others such as, but not limited to economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. These risk factors and others are included from time to time in filings made by the Company with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Contact information at: [email protected]

ENGLEWOOD, Colo., Dec. 10, 2020 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO), announced today it has supplied SAF to further support carbon neutrality goals in the aviation industry.

Gevo’s customer and global fuel supplier, Avfuel Corporation, delivered SAF to Leading Edge Jet Center, a provider of business aviation services throughout the Pacific Northwest, to deliver a demonstrative load of sustainable aviation fuel (SAF) to the fixed-base operator’s (FBO) Seattle facility.

The delivery marks the first load of sustainable aviation fuel for an FBO at the King County International Airport – Boeing Field (BFI) for resale to its customers, as well as Avfuel’s entry to SAF deliveries in Washington state.

“I want to congratulate Avfuel and Leading Edge Jet Center for making progress towards a cleaner future,” stated Patrick Gruber, Chief Executive Officer of Gevo. “We look forward to growing our business relationship and helping to educate aircraft operators and owners that products exist that burn cleaner and reduce carbon emission.”

To learn more about Gevo’s SAF please visit: https://gevo.com/products/sustainable-aviation-fuel/

About Gevo


Gevo is commercializing the next generation of jet fuel, gasoline and diesel fuel with the potential to achieve zero carbon emissions and address the market need of reducing greenhouse gas emissions with sustainable alternatives. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials, and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes. As a result, Gevo is able to produce low-carbon fuels with substantially reduced carbon intensity (as measured by the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their lifecycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the environmental problems of fossil-based carbon fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented, technology that enables the use of a variety of low-carbon sustainable feedstocks to produce price-competitive, low carbon products, such as jet fuel, gasoline components like isooctane and isobutanol and diesel fuel, yields the potential to generate project and corporate returns that justify the build-out of a multi-billion dollar business. Learn more at our website: www.gevo.com

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, including, without limitation, statements related to Gevo’s supply of sustainable aviation fuel to Avfuel and their customer and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2019 and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo. 

Investor & Media Contact
[email protected]
+1 720-647-9605

Mountain View, CA , Dec. 10, 2020 (GLOBE NEWSWIRE) — WSO2, the leader in digital transformation technology, today announced three executive promotions to support the next stage of the company’s global growth.

• Devaka Randeniya, chief revenue officer (CRO), previously served as senior vice president of worldwide sales at WSO2.
• Geethika Cooray, vice president and head of identity and access management (IAM) at WSO2, formerly was director and head of sales of IAM.
• Senaka Fernando, head of digital transformation, was a senior director of technology evangelism in the WSO2 CTO office.

Hundreds of the world’s largest corporations, top universities, and governments now rely on WSO2’s open source, cloud-native solutions to drive their digital transformation—executing over 6 trillion transactions annually. Using WSO2 for API management, integration, and customer identity and access management (CIAM), these organizations are harnessing the full power of their APIs to securely deliver the digital services and applications powering their businesses.

“We succeed when our customers succeed. No one understands that better than Devaka, Geethika and Senaka, who each bring years of expertise in helping our customers to effectively leverage our software and consulting in implementing their digital strategies,” said Dr. Sanjiva Weerawarana, WSO2 founder and CEO. “They will play strategic roles in ensuring our customers’ success as we accelerate global adoption and roll out our next generation of solutions for enabling secure, API-first digital services.”

Devaka Randeniya: Driving Revenues via Customers’ Success

As CRO, Devaka will drive global revenue generation by uniting all the teams that interact with customers behind a single vision for optimizing their relationships and providing a consistent, superior experience. The role builds on his success in leading the expansion of WSO2’s sales team and network of partners since joining the company as its first sales executive in 2006.

Most recently, as senior vice president of worldwide sales, Devaka has managed a global sales force of more than 60 sales executives, which collectively generates over $60 million in annual bookings. Earlier, as vice president of sales, he transformed the organization to reach EBITDA (earnings before interest, taxes, and amortization) profitable status in 2016. Prior to joining WSO2, Devaka was a business analyst in the research and development division of Virtusa Corporation, focusing on integration middleware and open source technologies.

Geethika Cooray: Leading IAM Expansion

As vice president and head of IAM at WSO2, Geethika leads the overall operations of WSO2’s Identity & Access Management Business Unit. The role builds on his success as director and head of sales – identity and access management where he spearheaded sales and go-to-market strategies that have rapidly accelerated global adoption of WSO2’s award-winning CIAM solutions.

Since joining WSO2 in 2011, Geethika has contributed to the company’s revenue growth in a number of sales positions, focusing on the North American market and some of WSO2’s largest customers. Before joining WSO2’s IAM BU in 2020, he had advanced to associate director, sales and territory manager – US Northeast. Geethika began his career at Unilever Sri Lanka – IT Dept where he was involved in its sales enablement applications and other IT initiatives.

Senaka Fernando: Defining Digital Strategies

As head of digital transformation, Senaka Fernando is responsible for defining, designing and delivering digital strategies for WSO2 customers and prospects. The role expands on his years of expertise in driving customers’ successful adoption and implementation of WSO2’s solutions—from his start as an engineer, to serving as a solutions architect, and most recently in his position as senior director of technology evangelism in the WSO2 CTO office.

Senaka is an elected member of the Apache Software Foundation (ASF), a Project Management Committee (PMC) member, and committer for a number of Apache projects. Additionally, he is a member of several Organization for the Advancement of Structured Information Standards (OASIS) technical committees.

About WSO2

Founded in 2005, WSO2 enables the composable enterprise. Our open source, API-first, and decentralized approach helps developers and architects to be more productive and rapidly build digital products to meet demand. Customers choose us for our broad, integrated platform, approach to open source, and digital transformation methodology. The company’s hybrid platform for developing, reusing, running, and managing integrations prevents lock-in through open source software that runs on-premises or in the cloud. With offices in Australia, Brazil, Germany, Sri Lanka, the UK, and the US, WSO2 employs over 600 engineers, consultants, and professionals worldwide. Today, hundreds of leading brands and thousands of global projects execute over 6 trillion transactions annually using WSO2 integration technologies. Visit https://wso2.com to learn more. Follow WSO2 on LinkedIn and Twitter.

Trademarks and registered trademarks are the properties of their respective owners.

Molly Ryner
Lewis Global Communications for WSO2
[email protected]
619-308-5238

VANCOUVER, British Columbia, Dec. 10, 2020 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is pleased to announce that it has engaged a globally recognized operations, compliance, and regulatory consulting firm to advise on the Company’s application to Health Canada for a Dealers Licence under the Controlled Drugs and Substances Act (CDSA).

The CDSA and its Regulations provide, among other things, the framework for legal access to controlled substances, and the control and regulation of production, distribution, and sale. One of Health Canada’s responsibilities is to provide the licensing and oversight framework for the legal production of controlled substances.

Under this framework, a company is required to obtain a licence issued by Health Canada in order to conduct various activities with controlled substances. Licence holders are responsible for compliance with the CDSA and its Regulations as well as compliance with other applicable federal, provincial, and territorial legislation and municipal by-laws. The issued licence dictates activities, conditions, and restrictions for the licence holder depending on licence permissions.

A Dealer’s Licence could allow for the following activities:

• Procurement of controlled substances, including by import, synthesis, propagation, cultivation and harvesting of psychedelic mushrooms for psilocybin extraction
• Research and manufacture of controlled substances such as psilocybin and psilocin
• Business to business sale of controlled substances, including by export
• Sale of controlled substance via pharmacies

Pure Extracts CEO, Ben Nikolaevsky, remarked, “Having the support of one of Canada’s premiere consulting companies with subject matter proficiency in cannabis and other regulated consumer product industries assures that we will submit a fully-compliant Dealers Licence application to Health Canada in the shortest time possible. As a plant-based extractor bringing functional mushroom products to market in Q1 2021, we are very excited to be laying the groundwork for our move into the controlled substances world of psychedelics.”

Having the ability to do extraction research and development into psychedelic compounds such as psilocybin and psilocin will prepare Pure Extracts to work with partners such as medical doctors, pharmaceutical company and pharmacies as clinical trials lead to the legalization of psychedelics and the advancement of micro-dosing in the near future.

Submission of the Company’s Dealer’s Licence application is subject to compliance with applicable securities laws, including any necessary approvals by the CSE.

The Company also announces that it has entered into an agreement with Market IQ Media Group on a month-to-month basis for marketing, communication, shareholder engagement and social media communication. The marketing and communication program will include certain investor relations activities and is designed to provide improved visibility in the Company’s current and planned operations.

About Pure Extracts

(
CSE: PULL
)
(XFRA: A2QJAJ)

The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/.

For further information please contact Empire Communications Group at (604) 343-2724.

ON BEHALF OF THE BOARD

“

Ben Nikolaevsky

”

Ben Nikolaevsky
CEO and Director

The CSE has neither approved nor disapproved the contents of this press release.

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. The Company is in the preliminary stages of preparing a Dealer’s License application and there is no certainty on the timing of such application, or that the Company will ultimately be successful is obtaining a Dealer’s License. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.

 

TUSTIN, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the pricing of an underwritten public offering of 3,333,335 shares of its common stock at a price to the public of $9.00 per share. The gross proceeds from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Avid Bioservices, Inc. The offering is expected to close on or about December 14, 2020, subject to customary closing conditions. Avid Bioservices, Inc. has also granted the underwriters a 30-day option to purchase from it up to an additional 500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Avid Bioservices, Inc. intends to use the net proceeds from the offering primarily for the expansion of its manufacturing capabilities and any remainder for general corporate purposes.

RBC Capital Markets is acting as sole book-running manager for the offering. Craig-Hallum Capital Group and Stephens Inc. are acting as co-managers for the offering.

The shares described above are being offered by Avid Bioservices, Inc. pursuant to a shelf registration statement on Form S-3 previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to the offering has also been filed with the SEC and is available on the SEC’s website at http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to this offering may be obtained from RBC Capital Markets, LLC, Attn: Equity Capital Markets, 200 Vesey Street, New York, NY 10281, by telephone at 877-822-4089 or by email at [email protected], Craig-Hallum Capital Group LLC, Attn: Equity Capital Markets, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, by telephone at (612) 334-6300 or by e-mail at [email protected] or from Stephens Inc., Attn: Equity Syndicate, 111 Center Street, Little Rock, AR 72201, by telephone at (501) 377-2000 or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any offer, sale or solicitation of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.

About
 
Avid
Bioservices
, Inc.

Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 27 years of experience producing monoclonal antibodies and recombinant proteins, Avid Bioservices, Inc.’s services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com.

Forward-Looking Statements

Statements in this press release which are not purely historical, including statements regarding Avid
Bioservices
, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the offering and the intended use of the net proceeds from the offering, and involve risks and uncertainties. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2020 and subsequent quarterly reports on Form 10-Q, as well as any updates to these risk factors filed from time to time in our other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release, and we disclaim any obligation, and do not undertake, to update or revise any forward-looking statements in this press release except as may be required by law. 

Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
[email protected]

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
[email protected]

Company to Host Fireside Chat with
Redmonk’s
James Governor on the Art of Observability and How to Implement an Observability Strategy

Virtual Booth Includes Demos, Trainings and Best Practices Sessions Across
DevSecOps
Including Deep Technical Sessions on Sumo Logic’s Cloud SIEM Solution

REDWOOD CITY, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) — Sumo Logic (Nasdaq: SUMO), the pioneer in continuous intelligence, today announced it will showcase its observability solutions at AWS re:Invent taking place from Nov. 30 to Dec. 18 to help AWS users get a unified view of key AWS services, accounts and regions. In addition, Sumo Logic’s Bruno Kurtic, VP of Strategy and Solutions, will host a fireside chat with James Governor, analyst and co-founder of Redmonk, on the art of observability and how to programmatically implement an observability strategy. The session will take place on Dec. 17 at 8:45 a.m. PT.

Cross-cutting approach to managing reliability of AWS-based apps

The shift from a siloed monitoring-only approach to observability is realized through reliability that ensures security, performance and availability across the application stack. Sumo Logic’s Observability solutions provide enterprises with a unified view of real-time analytics across a vast amount of application and infrastructure logs, metrics, traces and metadata.

Sumo Logic will showcase its observability solutions at its AWS re:Invent virtual booth, including the recently launched AWS Observability Solution — which leverages all of the telemetry generated by AWS services that accelerates issue resolution, automatically determines the root cause of any failure, and helps customers optimize usage of AWS services to improve uptime and performance.

Sumo Logic’s AWS Observability Solution takes a cross-cutting approach to managing reliability of AWS-based applications and underlying AWS services by easily and automatically ingesting, collecting, unifying and analyzing telemetry data from popular AWS services — such as Application Load Balancer, Amazon Elastic Compute Cloud (EC2), Amazon Relational Database (RDS), AWS Lambda, Amazon DynamoDB and Amazon API Gateway — in order to quickly detect anomalous events, determine timeline and scale of anomalies, and enable rapid root cause analysis through machine learning aided technology. It does all of this while keeping the raw data secure in case it contains sensitive information.

To monitor or observe: the million-dollar question

Modern distributed applications architected on AWS are built with agility as the primary goal. This agility creates multiple changing failure modes which means new approaches to management are needed. This Dec. 17 session, led by Sumo Logic’s Bruno Kurtic and Redmonk’s James Governor, explores the new art of ensuring overall system health by observing the system, and when a problem arises, using analytics to quickly identify the what, where and why of the problem. In addition, they will touch on the differences between monitoring and observability, the typical characteristics of an observable application, and how to programmatically implement observability. More information can be found here.

Expertise in the booth: security and observability

Sumo Logic will feature its expert team in its virtual booth now through Dec. 18 with live sessions being held daily from 11:45 a.m.- 3:45 p.m. PT, including:

• “
  Sumo Security in 60: Getting started with security using Sumo Logic” – a technical session geared toward practitioners across SecOps, DevOps and IT Ops. Discover how Sumo Logic’s Cloud SIEM solution delivers security analytics and makes audit and compliance easier for AWS and hybrid environments with SOC automation, out-of-the-box correlation rules, threat intelligence, AWS security benchmarking and more.

• Observability workshops – modernize businesses with detailed insight into the health of AWS stacks by getting hands-on with Sumo Logic’s observability solutions. Interactive learning exercises include troubleshooting with tracing and in-depth diagnosis with our root cause analysis tool.

• Demos – see Sumo Logic in action and dive deeper into security and observability solutions including: modern app observability, AWS observability, detecting AWS account compromise with Sumo Logic’s Cloud SIEM, security analytics using the power of AWS, and how to leverage the Sumo Logic platform for security and compliance and AWS Security benchmark.

• On Demand Sessions – attendees can access on-demand sessions that feature best practices for monitoring, troubleshooting and securing modern application as well as customer presentations.

The virtual booth schedule can be found here.

Additional Resources

• 
  Check out
  Sumo Logic’s virtual booth agenda at AWS re:Invent
• 
  Book a meeting
  with Sumo Logic at AWS re:Invent
• 
  Learn more
  about Sumo Logic’s AWS observability solution
• 
  Sign up
  for a free trial of Sumo Logic

About Sumo Logic

Sumo Logic Inc. (Nasdaq: SUMO) is the pioneer in continuous intelligence, a new category of software, which enables organizations of all sizes to address the data challenges and opportunities presented by digital transformation, modern applications, and cloud computing. The Sumo Logic Continuous Intelligence Platform™ automates the collection, ingestion, and analysis of application, infrastructure, security, and IoT data to derive actionable insights within seconds. More than 2,100 customers around the world rely on Sumo Logic to build, run, and secure their modern applications and cloud infrastructures. Only Sumo Logic delivers its platform as a true, multi-tenant SaaS architecture, across multiple use-cases, enabling businesses to thrive in the Intelligence Economy. For more information, visit www.sumologic.com.

Sumo Logic is a trademark or registered trademark of Sumo Logic in the United States and in foreign countries. All other company and product names may be trademarks or registered trademarks of their respective owners.

Any information regarding offerings, updates, functionality, or other modifications, including release dates, is subject to change without notice. The development, release, and timing of any offering, update, functionality, or modification described herein remains at the sole discretion of Sumo Logic, and should not be relied upon in making a purchase decision, nor as a representation, warranty, or commitment to deliver specific offerings, updates, functionalities, or modifications in the future.

Media Contacts

Melissa Liton
Sumo Logic
[email protected]
(650) 814-3882

Palm Beach, FL, Dec. 10, 2020 (GLOBE NEWSWIRE) — QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Cyclosam^® Samarium-153-DOTMP, for the treatment of cancer and related diseases and conditions, announced today that the European Patent Office (EPO) has allowed the first patent covering “DOTMP kit formulations for radioisotopes.” This is the first patent outside the United States and is in addition to the two prior patents issued by the United States Patent & Trademark Office (USPTO) covering “High purity and low specific activity therapeutic bone agents.”

The EPO patent allowance covers technology licensed exclusively by QSAM from IGL Pharma, Inc. that protects the radiopharmacy preparation of CycloSam. The DOTMP kits, which refer to the chelating agent that binds the radioisotopes to growing cells in the bone and is believed by management to reduce toxicity and increase efficacy of the drug candidate, are a crucial component of the Cyclosam radiopharmaceutical product.

“We are pleased that the EPO has recognized the novelty of our scientific discoveries and innovations by allowing our first patent outside the United States. This enhances our entire IP estate which currently covers 15 total patents across 3 distinct patent families all of which are in various stages of prosecution and issuance both in the United States and internationally,” stated Douglas R. Baum, CEO of the Company. “We expect additional patents to be issued through our exclusive worldwide license agreement with IGL Pharma, as we add patent filings in the coming year.”

About QSAM Biosciences:

QSAM Bioscience, Inc. holds the worldwide license for CycloSam^® (Samaium-153 DOTMP), a clinical stage novel radiopharmaceutical meant to treat different types of bone cancer and related diseases. QSAM’s initial technology is Samarium-153 DOTMP, aka CycloSam^®, a clinical-staged bone targeting radiopharmaceutical​ developed by IsoTherapeutics Group LLC, leaders in the nuclear medicine space who also developed FDA-approved and commercially available Quadramet^® (Samarium-153 EDTMP), indicated for pain palliation. CycloSam was assigned to IsoTherapeutics Group’s subsidiary, IGL Pharma, Inc.

CycloSam^® has already demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared successful human trial performed earlier in 2020. This nuclear technology uses low specific activity Samarium-153 (resulting in far less europium) and DOTMP, a chelator which is believed to eliminate off-target migration and targets sites of high bone turn over making it an ideal agent to treat osteosarcoma or other bone metastases. Osteosarcoma is the most common malignant bone tumor among children and adolescents. Because of its ability to deliver radiation to the skeletal system, it is also believed to be an effective agent to perform bone marrow ablation as pre-conditioning for bone marrow transplantation. This drug candidate utilizes an FDA approved radioisotope combined with a novel chelant that has demonstrated increased efficacy and decreased side effects in animal models. Further, CycloSam^® utilizes a streamlined, just-in-time manufacturing process. Given these factors, management believes there is a strong pathway to commercialization.

CycloSam^® is cleared by the FDA under an investigator initiated IND to commence human dosing immediately in patients with osteosarcoma and bone metastasis. CycloSam^® was also cleared by FDA and successfully used under a single-patient IND to perform bone marrow ablation prior to allogenic marrow transplantation (BMA/T) in 2020.

Legal Notice Regarding Forward-Looking Statements: This news release contains “Forward-looking Statements”. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. We disclaim any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to our ability to fully commercialize our technology, risks associated with changes in general economic and business conditions, actions of our competitors, the extent to which we are able to develop new products and markets, the time and expense involved in such development activities, the ability to secure additional financing, the ability to consummate acquisitions and ultimately integrate them, the level of demand and market acceptance of our products, and changes in our business strategies. This is not an offering of securities and securities may not be offered or sold absent registration or an applicable exemption from the registration requirements

Contact

Christopher Nelson
[email protected]